Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep demonstrates 69% ORR in pancreatic cancer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5340)
•••
Comment by Noteableon Oct 22, 2023 10:42am
99 Views
Post# 35695244

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancerShould read : TCRs typically recognise antigen within the context of an MHC molecule and the expansion of cytotoxic CD8+ immune effector T cells. which serves both as an adhesion molecule for class I MHC molecules and as a coreceptor with the TCR for T cell activation.

ONCY Aware-1 and Bracelet-1 breast cancer clinical studies tat treatment with pelareorep demonstrated the expansion of cytotoxic CD8+ immune effector T cells vs immunosuppressive Treg cells.

In so doing, ONCY showed how pelareorep is able to remodel the tumor microenvironment (TME) and turn cold tumors, like pancreatic cancer, into ‘hot’ inflamed tumors that are demonstrate high responses to immune checkpoint inhibitors (CPIs). 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities